摘要
在已故供者中,缺血/再灌注损伤(IRI)是导致移植肾功能障碍的重要原因。长时间的冷和热缺血时间会导致移植后早期并发症的高风险,包括急慢性排斥反应。缺血不仅能上调炎症细胞因子和趋化因子,还能促进mhc-Ⅱ类和粘附分子在上皮和上皮上的表达。树突状细胞。此外,应激或死亡细胞释放出的危险相关分子模式(DAMP)不仅会引起或放大组织炎症,并在反应t中触发组织修复。OIRI,同时也是增强DC成熟和增强适应性免疫反应的佐剂。在这次检讨中,我们亦会讨论捐赠区或接受区议会在缺血过程增强了急性排斥反应。
关键词: 树突状细胞,肾移植,同种异体排斥反应,缺血/再灌注损伤,APC,CTL。
Current Gene Therapy
Title:How Do Dendritic Cells Play the Role in Ischemia/Reperfusion Triggered Kidney Allograft Rejection
Volume: 17 Issue: 6
关键词: 树突状细胞,肾移植,同种异体排斥反应,缺血/再灌注损伤,APC,CTL。
摘要: In deceased donors, Ischemia/Reperfusion Injury (IRI) is an important cause of allograft dysfunction. Prolonged cold and warm ischemia time leads to a high risk of early post-transplant complications, including acute and chronic rejection. Ischemia not only up-regulates inflammatory cytokines and chemokines, but also enhances the expression of MHC-class II and adhesion molecules on epithelial and dendritic cells. Moreover, the Danger Associated Molecular Patterns (DAMPs) released from stressed or dying cells, not only cause or amplify tissue inflammation and trigger tissue repair in response to IRI, but also act as adjuvants that enhance DC maturation and potentiate the adaptive immune response. In this review, we will also discuss about whether donor or recipient DCs are more important in the process of ischemia enhanced acute rejection.
Export Options
About this article
Cite this article as:
How Do Dendritic Cells Play the Role in Ischemia/Reperfusion Triggered Kidney Allograft Rejection, Current Gene Therapy 2017; 17 (6) . https://dx.doi.org/10.2174/1566523218666180214095956
DOI https://dx.doi.org/10.2174/1566523218666180214095956 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions
Current Pharmaceutical Design Melatonin Could Be Beneficial in SARS-CoV-2 Therapy
The Natural Products Journal “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Recent Advances in the Discovery of Tissue Factor/Factor VIIa Inhibitors and Dual Inhibitors of Factor VIIa/Factor Xa
Current Pharmaceutical Design Detrimental Effects of Hyperglycemia in Acute Coronary Syndromes: from Pathophysiological Mechanisms to Therapeutic Strategies
Mini-Reviews in Medicinal Chemistry The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Mass Spectrometric Quantification of Urinary Netrin-1 Protein in Renal Transplant Recipients
Current Proteomics Adenosine and Adenosine Receptors: Their Contribution to Airway Inflammation and Therapeutic Potential in Asthma
Current Medicinal Chemistry Recent Advances in Health Promoting Effect of Dietary Polyphenols
Current Nutrition & Food Science Dual COX Inhibition and Upper Gastrointestinal Damage
Current Pharmaceutical Design Clinical Applications of Cardiac Multi-Slice Computed Tomography
Current Medical Imaging Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Mechanical Intervention for Acute Myocardial Infarction
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Coagulopathy as a Therapeutic Target for TRALI: Rationale and Possible Sites of Action
Current Pharmaceutical Design Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design Anti-Aging Drugs – Prospect of Longer Life?
Current Medicinal Chemistry EGF Receptor as a Drug Target in Arterial Hypertension
Mini-Reviews in Medicinal Chemistry Evaluation of Clinical Efficacy of Fasudil for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery A Review of Neuroprotective Agents
Current Medicinal Chemistry Fetal Asphyctic Preconditioning Protects Against Perinatal Asphyxia- Induced Apoptosis and Astrogliosis in Neonatal Brain
CNS & Neurological Disorders - Drug Targets Industrial Production of the Cell Protectant Ectoine: Protection Mechanisms, Processes, and Products
Current Biotechnology